A Phase II Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin (Caelyx) and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Patients With Locally Advanced Breast Cancer.

Trial Profile

A Phase II Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin (Caelyx) and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Patients With Locally Advanced Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2013

At a glance

  • Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Doxorubicin liposomal (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 01 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top